Edition:
United Kingdom

Abbvie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

64.43USD
16 Aug 2019
Change (% chg)

$1.45 (+2.30%)
Prev Close
$62.98
Open
$63.51
Day's High
$64.81
Day's Low
$63.07
Volume
1,840,851
Avg. Vol
2,126,206
52-wk High
$100.23
52-wk Low
$62.68

Select another date:

Fri, Aug 16 2019

Photo

AbbVie prices new rheumatoid arthritis drug at $59,000 a year

AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising competition for Humira, its blockbuster therapy for the same condition.

UPDATE 2-AbbVie prices new rheumatoid arthritis drug at $59,000/yr

Aug 16 AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising competition for Humira, its blockbuster therapy for the same condition.

FDA approves AbbVie's new rheumatoid arthritis drug

Aug 16 The U.S. Food and Drug Administration on Friday approved AbbVie Inc's new treatment for rheumatoid arthritis, a win for the drugmaker seeking to widen its portfolio as its blockbuster flagship therapy Humira faces competition.

Allergan beats profit, raises revenue forecast on Restasis, Juvederm demand

Allergan Plc , which is being bought by AbbVie Inc for $63 billion, beat quarterly profit estimates and raised its 2019 revenue forecast on Tuesday, helped by demand for its dry eye drug Restasis and aesthetics product Juvederm.

Allergan beats profit, raises revenue forecast on Restasis, Juvederm demand

Aug 6 Allergan Plc, which is being bought by AbbVie Inc for $63 billion, beat quarterly profit estimates and raised its 2019 revenue forecast on Tuesday, helped by demand for its dry eye drug Restasis and aesthetics product Juvederm.

AbbVie spotlights Allergan deal, new drugs as Humira sales wane

AbbVie Inc said on Friday a combination of new drugs in its arsenal and its planned $63 billion deal for Botox-maker Allergan Plc will counter declining sales of its long-time bestseller, Humira.

UPDATE 3-AbbVie spotlights Allergan deal, new drugs as Humira sales wane

July 26 AbbVie Inc said on Friday a combination of new drugs in its arsenal and its planned $63 billion deal for Botox-maker Allergan Plc will counter declining sales of its long-time bestseller, Humira.

AbbVie does not expect to divest new psoriasis drug

AbbVie Inc said on Friday it does not expect the Federal Trade Commission would require divestiture of its recently approved psoriasis drug Skyrizi in connection with the company's $63 billion pending deal to buy Allergan Plc .

AbbVie does not expect to divest new psoriasis drug

July 26 AbbVie Inc said on Friday it does not expect the Federal Trade Commission would require divestiture of its recently approved psoriasis drug Skyrizi in connection with the company's $63 billion pending deal to buy Allergan Plc.

AbbVie raises 2019 profit target as quarterly sales beat estimates

July 26 Drugmaker AbbVie Inc on Friday raised its earnings forecast for the year and beat Wall Street estimates for second-quarter revenue, as sales of its top-selling drug Humira did not fall as much as analysts had feared.

Select another date: